Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$131.11 -1.2%	$123.43	$110.04 ▼ $238.00	$19.21B	0.12	1.41 million shs	3.64 million shs
HALO Halozyme Therapeutics	$55.98 +2.3%	$58.91	$42.01 ▼ $70.51	$6.90B	1.26	1.63 million shs	2.23 million shs
INCY Incyte	$65.25 -1.2%	$60.80	$53.56 ▼ $83.95	$12.63B	0.68	2.30 million shs	3.74 million shs
UTHR United Therapeutics	$316.34 -1.3%	$299.49	$266.98 ▼ $417.82	$14.27B	0.58	443,403 shs	886,326 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.24%	+4.21%	+8.28%	-6.68%	-38.85%
HALO Halozyme Therapeutics	+2.28%	+2.64%	-8.86%	-5.36%	+30.92%
INCY Incyte	-1.20%	+1.56%	+4.13%	-11.22%	+14.63%
UTHR United Therapeutics	-1.26%	+2.82%	+4.37%	-1.13%	+18.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.8015 of 5 stars	4.2	3.0	3.7	3.4	2.5	1.9
HALO Halozyme Therapeutics	4.8131 of 5 stars	3.1	1.0	4.4	3.3	2.5	4.4
INCY Incyte	4.6169 of 5 stars	3.1	2.0	3.1	2.9	3.3	3.1
UTHR United Therapeutics	4.8793 of 5 stars	3.3	2.0	4.6	3.9	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$191.30	45.91% Upside
HALO Halozyme Therapeutics	2.17	Hold	$61.90	10.58% Upside
INCY Incyte	2.17	Hold	$73.60	12.80% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$392.00	23.92% Upside

Current Analyst Ratings Breakdown

Latest HALO, BIIB, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/27/2025	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$72.00 ➝ $73.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2025	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$47.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/7/2025	HALO Halozyme Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $65.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
5/2/2025	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$205.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	1.96	$21.53 per share	6.09	$114.71 per share	1.14
HALO Halozyme Therapeutics	$1.08B	6.36	$4.53 per share	12.35	$2.95 per share	18.98
INCY Incyte	$4.41B	2.86	$0.51 per share	128.94	$17.82 per share	3.66
UTHR United Therapeutics	$2.99B	4.77	$19.02 per share	16.63	$127.35 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.72	7.94	1.51	16.87%	14.98%	8.76%	8/7/2025 (Estimated)
HALO Halozyme Therapeutics	$281.59M	$3.76	16.32	9.00	0.42	43.74%	157.78%	25.34%	8/5/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	241.68	9.98	0.41	0.77%	0.05%	0.04%	7/29/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$25.06	13.89	11.51	0.97	40.31%	19.22%	16.15%	7/30/2025 (Estimated)

Latest HALO, BIIB, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
HALO Halozyme Therapeutics	4.14	7.80	9.15
INCY Incyte	0.01	1.97	1.94
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
HALO Halozyme Therapeutics	97.79%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
HALO Halozyme Therapeutics	2.90%
INCY Incyte	17.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.20 million	Optionable
INCY Incyte	2,320	193.57 million	159.46 million	Optionable
UTHR United Therapeutics	980	45.11 million	39.33 million	Optionable

HALO, BIIB, UTHR, and INCY Headlines

Recent News About These Companies

Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?

May 30 at 12:37 PM | zacks.com

13,541 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Lansforsakringar Fondforvaltning AB publ

May 30 at 5:32 AM | marketbeat.com

Public Employees Retirement System of Ohio Sells 1,090 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 30 at 4:22 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of "Moderate Buy" by Brokerages

May 30 at 3:06 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Voloridge Investment Management LLC

May 29 at 4:29 AM | marketbeat.com

Polar Asset Management Partners Inc. Takes $7.80 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

May 28 at 5:51 AM | marketbeat.com

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

May 27, 2025 | benzinga.com

GF Fund Management CO. LTD. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

May 27, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)

May 27, 2025 | marketbeat.com

Two Sigma Advisers LP Has $4.16 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 27, 2025 | marketbeat.com

Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod

May 27, 2025 | msn.com

Quantinno Capital Management LP Buys 1,003 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 26, 2025 | marketbeat.com

Q2 EPS Forecast for United Therapeutics Reduced by Analyst

May 25, 2025 | marketbeat.com

Q3 EPS Estimate for United Therapeutics Reduced by Analyst

May 24, 2025 | marketbeat.com

Tidal Investments LLC Sells 1,567 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 24, 2025 | marketbeat.com

ProShare Advisors LLC Trims Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 24, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,342 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 24, 2025 | marketbeat.com

Zacks Research Analysts Reduce Earnings Estimates for UTHR

May 24, 2025 | americanbankingnews.com

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings

May 24, 2025 | americanbankingnews.com

Liquidia's Yutrepia gets FDA approval for added indication

May 23, 2025 | msn.com

MidWestOne Financial Group Inc. Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO, BIIB, UTHR, and INCY Company Descriptions

Biogen NASDAQ:BIIB

$131.11 -1.64 (-1.24%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$130.04 -1.07 (-0.81%)

As of 05/30/2025 05:47 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics NASDAQ:HALO

$55.98 +1.25 (+2.28%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$55.12 -0.86 (-1.54%)

As of 05/30/2025 07:17 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Incyte NASDAQ:INCY

$65.25 -0.79 (-1.20%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$64.00 -1.25 (-1.92%)

As of 05/30/2025 05:55 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$316.34 -4.03 (-1.26%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$316.78 +0.44 (+0.14%)

As of 05/30/2025 06:48 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time